Mineralys Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, 121.36, 254.69, 681.99, 1129.4 ], "ebit_estimate": [ -203.48, -238.01, -17.24, 191.88, 528.34 ], "ebitda_estimate": [ -191.32, -103.91, -91.47, 188.01, 678.58 ], "net_income_estimate": [ -187.31, -184.39, -105.4, 192.83, 461.42 ], "per_share_eps_estimate": [ -2.28, -2.05, -1.13, 2.07, 4.59 ], "eps_nri_estimate": [ -2.17, -2.1, -1.17, 1.95, 4.42 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -187.31, -181.02, -106.88, 203.1, 540.61 ], "operating_cash_flow_per_share_estimate": [ -2.38, 1.13, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ -39.23, null, null, null, null ], "gross_margin_estimate": [ null, 82, 82.5, 83, 83.5 ], "operating_cash_flow_estimate": [ -197.15, 93.6, null, null, null ], "pettm_estimate": [ 0, 0, 0, 13.74, 6.19 ], "long_term_growth_rate_mean": 18.61, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 19.95, "future_eps_nri_estimate_growth": 18.61, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 48.93, "future_ebitda_estimate_growth": 21.96, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, 2, 14, 23.67, 40.83 ], "ebit_estimate": [ -48.66, -52.18, -58.03, -72.6, -59.87, -59.27, -54.57 ], "ebitda_estimate": [ -47.39, -46.67, -54.11, -101.8, null, null, null ], "net_income_estimate": [ -46.26, -50.47, -56.81, -58.67, -56.03, -55.43, -50.4 ], "per_share_eps_estimate": [ -0.54, -0.58, -0.64, -0.69, -0.65, -0.62, -0.55 ], "eps_nri_estimate": [ -0.53, -0.56, -0.62, -0.79, -0.65, -0.62, -0.55 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -45.07, -50.28, -55.43, -58.67, -56.03, -55.43, -50.4 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 18.61, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 19.95, "future_eps_nri_estimate_growth": 18.61, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 48.93, "future_ebitda_estimate_growth": 21.96, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }